Safety, toxicology & handling

Anyone working with a nanotube asks the same first question: is it safe to handle? For boron nitride nanotubes the honest answer is nuanced — the published studies are broadly encouraging but far from complete, and the result depends heavily on how pure and how well-characterised the material is. This page summarises what the peer-reviewed literature actually says, neutrally.

Not safety advice. This is a literature summary for orientation, not health, safety, or regulatory guidance. It is not a substitute for a supplier's Safety Data Sheet (SDS), a risk assessment, or applicable occupational-health regulation. Always follow the SDS for the specific material you hold and consult a qualified EHS professional before handling nanomaterials.

Why "is BNNT toxic?" has no one-word answer

Two things make a blanket verdict impossible. First, purity varies enormously: as-produced BNNT can contain amorphous boron nitride, unreacted elemental boron, and — for catalytic routes — residual metal catalyst, and several studies attribute observed toxicity to those impurities rather than to the tubes themselves. Second, morphology matters: BNNT is a high-aspect-ratio fibre, and the toxicology of long, thin, biopersistent fibres is treated with caution as a class. Add in cell type, dose, dispersion, and how carefully the material was characterised, and two rigorous studies can reach opposite conclusions about "BNNT" while both being correct about what they actually tested.

What the studies report

Encouraging

Pristine BNNT is often well tolerated

An influential 2009 study reported that boron nitride nanotubes were non-cytotoxic to human cells and could be functionalised for biological interaction, and a body of work since has explored BNNT for drug delivery and tissue engineering on the basis of good biocompatibility in vitro.

Cautionary

Other studies report real toxicity

The record is genuinely mixed. A 2011 study found BNNTs cytotoxic across every cell type tested — in most cases more so than the carbon nanotubes it compared against — with severity depending on cell type. Later work on a commercial-grade BNNT mixture (only ~50–60% tubes, the rest boron and hexagonal BN) reported dose-dependent cytotoxicity in vitro and lung inflammation in vivo broadly comparable to a benchmark multi-walled carbon nanotube. "BNNT" is not one standardised substance, and some forms are clearly bioactive.

The most useful single entry point is a 2018 review in Biomaterials Science surveying boron nitride nanomaterials' biocompatibility and bio-applications; it, and the primary studies above, are collected with links in the reference library.

The fibre-shape question

Because BNNTs are long, thin, and durable, they invite comparison with other respirable fibres, and the fibre-pathogenicity framework — length, aspect ratio, and biopersistence as risk factors — is the right lens to apply until BNNT-specific inhalation data are more complete. The published inhalation and long-term in-vivo dataset for BNNT is still limited relative to the far larger literature on carbon nanotubes and asbestos. Absence of evidence of harm is not evidence of safety; it is a reason to handle the material conservatively.

Practical handling principles

These are the standard precautions applied to dry, potentially-respirable engineered nanomaterials — again, subordinate to the specific SDS and your local rules:

Contain the dust. Dry BNNT powder is the main exposure route. Handle in a fume hood, glovebox, or under local exhaust ventilation; avoid actions that aerosolise it.
Protect the airway. Respiratory protection appropriate to fine fibres/particulates, plus gloves, eye protection, and a lab coat, per your risk assessment.
Prefer the wet or bound state. Dispersions, pastes, and cured composites present far less inhalation risk than loose powder. Many workflows keep the material wet from the moment the container opens.
Control the residue. Wet-wipe surfaces, capture waste as directed by the SDS, and treat catalyst-bearing as-produced material as potentially more hazardous than purified, characterised tubes.
Know your material. Ask the supplier for purity, catalyst content, and any available toxicological data. Purity is a safety parameter, not only a performance one.

The honest bottom line

Promising, but not settled. Purified, well-characterised boron nitride nanotubes have looked biocompatible in a number of published in-vitro studies, which is why biomedical uses are actively explored — but other rigorous work has found clear cytotoxicity, the outcome depends on cell type, dose, dispersion, and purity, the long-term inhalation dataset is thin, and the fibre morphology warrants precaution. The defensible position today is: treat BNNT as a nanomaterial to be handled carefully and by the book, watch the literature as it matures, and never generalise a result from one grade of material to another.

The therapeutic flip side: BNNT in medicine → · Purifying & working with BNNT →